CoCites: A citation-based method for searching scientific literature

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.

Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
Times Cited: 29

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord, Kathy J Agnew, Colin C Pritchard, Sheena Scroggins, Rochelle L Garcia, Mary-Claire King, Elizabeth M Swisher. Clin Cancer Res 2014
Times Cited: 547

List of shared articles

Times cited

Regulation and pharmacological targeting of RAD51 in cancer.
McKenzie K Grundy, Ronald J Buckanovich, Kara A Bernstein. NAR Cancer 2020

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Razan Sheta, Magdalena Bachvarova, Marie Plante, Marie-Claude Renaud, Alexandra Sebastianelli, Jean Gregoire, Jamilet Miranda Navarro, Ricardo Bringas Perez, Jean-Yves Masson, Dimcho Bachvarov. J Transl Med 2020

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
Lise M van Wijk, Andreea B Nilas, Harry Vrieling, Maaike P G Vreeswijk. Expert Rev Mol Diagn 2022

DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
Kristyna Tomasova, Andrea Cumova, Karolina Seborova, Josef Horak, Kamila Koucka, Ludmila Vodickova, Radka Vaclavikova, Pavel Vodicka. Cancers (Basel) 2020